Preclinical and clinical studies have demonstrated a synergistic effect when immune checkpoint inhibitors are combined with anti-Human Epidermal Growth Factor Receptor 2 (HER2) therapy to treat HER2-positive breast or gastric cancers [59,60,61]. This evidence concerns the gene ERBB2 and gastric cancer.